Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Neuronetics stock

Own Neuronetics stock in just a few minutes.


Fact checked

Neuronetics, Inc is a diagnostics & research business based in the US. Neuronetics shares (STIM) are listed on the NASDAQ and all prices are listed in US Dollars. Neuronetics employs 122 staff and has a trailing 12-month revenue of around USD$51 million.

How to buy shares in Neuronetics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Neuronetics. Find the stock by name or ticker symbol: STIM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neuronetics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Neuronetics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Neuronetics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Neuronetics share price

Use our graph to track the performance of STIM stocks over time.

Neuronetics shares at a glance

Information last updated 2020-11-25.
52-week range USD$1.26 - USD$8.57
50-day moving average USD$6.4275
200-day moving average USD$4.0402
Wall St. target price USD$9.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.435

Buy Neuronetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Neuronetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neuronetics financials

Revenue TTM USD$51 million
Gross profit TTM USD$47.3 million
Return on assets TTM -17.2%
Return on equity TTM -76.64%
Profit margin -61.45%
Book value $1.449
Market capitalisation USD$153 million

TTM: trailing 12 months

Shorting Neuronetics shares

There are currently 814,042 Neuronetics shares held short by investors – that's known as Neuronetics's "short interest". This figure is 1.2% down from 823,814 last month.

There are a few different ways that this level of interest in shorting Neuronetics shares can be evaluated.

Neuronetics's "short interest ratio" (SIR)

Neuronetics's "short interest ratio" (SIR) is the quantity of Neuronetics shares currently shorted divided by the average quantity of Neuronetics shares traded daily (recently around 220011.35135135). Neuronetics's SIR currently stands at 3.7. In other words for every 100,000 Neuronetics shares traded daily on the market, roughly 3700 shares are currently held short.

However Neuronetics's short interest can also be evaluated against the total number of Neuronetics shares, or, against the total number of tradable Neuronetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neuronetics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Neuronetics shares in existence, roughly 40 shares are currently held short) or 0.044% of the tradable shares (for every 100,000 tradable Neuronetics shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neuronetics.

Find out more about how you can short Neuronetics stock.

Neuronetics share dividends

We're not expecting Neuronetics to pay a dividend over the next 12 months.

Neuronetics share price volatility

Over the last 12 months, Neuronetics's shares have ranged in value from as little as $1.26 up to $8.57. A popular way to gauge a stock's volatility is its "beta".

STIM.US volatility(beta: 2.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neuronetics's is 2.4997. This would suggest that Neuronetics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Neuronetics overview

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site